Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 256-360-6
CAS number: 48145-04-6
2-phenoxyethyl acrylate demonstrate a low acute oral and dermal
toxicity. No conclusive inhalation study is available.
The acute toxicity of phenoxyethyl acrylate was tested in a single dose
acute toxicity test, comparable to OECD Guideline 401. Two doses were
tested 2150 and 5000 mg/kg. The substance was giving orally dissolved in
olive oil, total volume was 5 and 10 ml/kg bw, which is acceptable
according to the OECD guideline. Several clinical signs were observed,
such as dyspnoea, shaggering, shaggy fur, redness of skin and hemi
paralysis. The symptoms gradually ceased within hours to two days,
except shaggy fur in the highest dose. No mortality was observed at any
of the doses, therefore the acute LD50 value is above 5000 mg/kg.
Rats of both sexes were given 2 g/kg as a single dermal exposure and
followed 14 days after exposure.
The substance can not be considered acutely toxic via the dermal route.
The available studies on acute toxicity of 2-phenoxyethyl acrylate
show that the substance has low acute toxicity. No mortality was
observed in the studies available (oral and dermal). In the oral
toxicity study using single dose levels of 2150 and 5000 mg/kg, several
clinical signs of toxicity were observed including dyspnoea, shaggering,
shaggy fur, redness of skin and hemi paralysis. The symptoms gradually
ceased within hours to two days except for the highest dose level. In
the dermal toxicity study, rats were given 2000 mg/kg as a single dermal
exposure. Neither clinical signs nor macroscopic abnormalities were
observed. A slight or well defined erythema was observed at the site of
application on day 2. No other dermal changes were observed and
irritation had resolved at day 3.
Supplementary information available from non-GLP studies using
inhalation (rat) and interperitoneal (mice) exposure routes. Using doses
of 215, 464 and 700 mg/kg bw interperitoneally the LD50 was
identified as > 464 mg/kg bw < 700
mg/kg bw based on no deaths at 215 and 464 mg/kg bw and 10/10 deaths at
700 mg/kg bw after 14 days. For the inhalational study, detailed
information on doses not available. After 7h exposure, no deaths
Overall, 2-phenoxyethyl acrylate demonstrates a low acute oral and
dermal toxicity. No conclusive inhalation key study is available.
Justification for selection of acute toxicity – oral endpoint
The study is an OECD Guideline 401 study
Justification for selection of acute toxicity – inhalation endpoint
No conclusive inhalation study available. Annex VIII requirement for
second exposure route is fulfilled as both an acute oral and an acute
dermal expossure study is availabe.
Justification for selection of acute toxicity – dermal endpoint
The study was performed according to EU Method B 3, under GLP
The available data on acute toxicity indicate that 2-phenoxyethyl
acrylate should not be CLP classified for acute toxicity in relation to
oral, dermal or inhalationl exposure.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again